No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among patients on dialysis. Cardiovascular risk was 36% higher with denosumab. Among adults ...

A HEARTBROKEN mum says she “nearly died” hearing her little girl’s diagnosis – after the tot’s face kept swelling following a ...

TUESDAY, Jan. 7, 2025 (HealthDay News) -- For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for ...

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

a proposed denosumab biosimilar to Amgen’s PROLIA and XGEVA. GlyCoNex is a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies. The licensee ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...